Wuxi Zhikang Hongyi Biotechnology
Innovative oncology solutions with advanced WEE1 inhibitors for late-stage ovarian cancer treatment.
| Date | Investors | Amount | Round |
|---|---|---|---|
* | CNY200m | Series A | |
| Total Funding | 000k | ||
BioCity Pharma specializes in developing cutting-edge oncology treatments, focusing on late-stage ovarian cancer. The company operates in the biopharmaceutical market, targeting healthcare providers and research institutions. Its business model revolves around the research, development, and commercialization of novel cancer therapies, particularly WEE1 small molecular inhibitors like SC0191. Revenue is generated through clinical trials, partnerships with pharmaceutical companies, and eventual drug sales upon regulatory approval. BioCity Pharma's recent achievement includes obtaining implicit authorization from the National Drug Supervisory Authority (NMPA) for SC0191, which will be used in conjunction with chemotherapy drugs for advanced ovarian cancer. This marks the third clinical permit for the SC0191 project, with the company poised to commence Ib II phase clinical research soon.
Keywords: oncology, WEE1 inhibitors, ovarian cancer, biopharmaceutical, clinical trials, SC0191, chemotherapy, NMPA approval, drug development, cancer treatment.